XMP0 Stock Overview A clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. More details
Rewards Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Plus Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Plus Therapeutics Historical stock prices Current Share Price US$1.15 52 Week High US$2.42 52 Week Low US$0.93 Beta 0.69 1 Month Change -8.45% 3 Month Change -6.06% 1 Year Change -38.21% 3 Year Change -90.97% 5 Year Change -96.86% Change since IPO -100.00%
Recent News & Updates
Insufficient new directors Dec 30
Plus Therapeutics, Inc. Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases At the 2024 San Antonio Breast Cancer Symposium Dec 18
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference Nov 26
CNSide Diagnostics, LLC to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases Nov 22
Third quarter 2024 earnings released: US$0.37 loss per share (vs US$1.00 loss in 3Q 2023) Nov 17
New major risk - Revenue and earnings growth Nov 16 See more updates
Insufficient new directors Dec 30
Plus Therapeutics, Inc. Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases At the 2024 San Antonio Breast Cancer Symposium Dec 18
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference Nov 26
CNSide Diagnostics, LLC to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases Nov 22
Third quarter 2024 earnings released: US$0.37 loss per share (vs US$1.00 loss in 3Q 2023) Nov 17
New major risk - Revenue and earnings growth Nov 16
Plus Therapeutics, Inc. to Report Q3, 2024 Results on Nov 14, 2024 Nov 05
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting Oct 01
Plus Therapeutics, Inc. Provides Non-Compliance Update Sep 09
Second quarter 2024 earnings released: US$0.45 loss per share (vs US$0.59 loss in 2Q 2023) Aug 16
Plus Therapeutics, Inc. to Report Q2, 2024 Results on Aug 14, 2024 Aug 08
Plus Therapeutics, Inc. Receives the Resignation of Dr. Norman Lafrance, Its Chief Medical Officer, Effective June 12, 2024 Jun 10
New major risk - Share price stability Jun 05
Plus Therapeutics, Inc., Annual General Meeting, Aug 15, 2024 May 22
First quarter 2024 earnings released: US$0.76 loss per share (vs US$2.07 loss in 1Q 2023) May 17
Plus Therapeutics, Inc. to Report Q1, 2024 Results on May 15, 2024 May 15
New major risk - Revenue and earnings growth May 12 Plus Therapeutics, Inc. announced that it has received $7.262078 million in funding from Aigh Capital Management, LLC Plus Therapeutics, Inc. announced that it expects to receive $17.948504 million in funding from Aigh Capital Management, LLC May 07
Plus Therapeutics, Inc. Receives $3 Million Award Recommendation from the United States Department of Defense Apr 23
Plus Therapeutics, Inc. Announces Validation & Clinical Implementation of Csf-01 Leptomeningeal Cancer Cell Diagnostic Mar 27
Plus Therapeutics Receives Non-Compliance Update from Nasdaq Mar 15
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases Mar 11
Full year 2023 earnings released: US$4.24 loss per share (vs US$11.58 loss in FY 2022) Mar 06
Plus Therapeutics, Inc. to Report Q4, 2023 Results on Mar 05, 2024 Feb 28
Insufficient new directors Dec 02 Plus Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $15.9375 million. Nov 24
Plus Therapeutics, Inc. has filed a Follow-on Equity Offering. Nov 23
Plus Therapeutics, Inc. Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting Nov 21
New major risk - Shareholder dilution Nov 05
Plus Therapeutics, Inc. (NasdaqCM:PSTV) announces an Equity Buyback for $0.5 million worth of its shares. Nov 01
Plus Therapeutics, Inc. to Report Q3, 2023 Results on Oct 31, 2023 Oct 24
Plus Therapeutics, Inc. Completes Dosing in Cohort 4 of ReSPECT-LM Phase 1 Clinical Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases Oct 11
Plus Therapeutics, Inc. Initiates Part B of ReSPECT-LM Phase 1/2a Trial for Leptomeningeal Metastase Sep 06
Plus Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023 Aug 09
Plus Therapeutics, Inc. Appoints Pius Maliakal as Vice President of Clinical Operations Jul 28
Plus Therapeutics, Inc. Reports Positive Interim Updates from Two Respect Clinical Trials at SNMMI Annual Meeting Jun 30
Plus Therapeutics, Inc. to Report Q4, 2022 Results on Feb 23, 2023 Feb 15
Plus Therapeutics, Inc. Completes Enrollment in Second ReSPECT-LM Phase 1 Trial Cohort of Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases Feb 02
Plus Therapeutics Announces First Patient Dosed in ReSPECT-GBM Phase 2b Trial of Rhenium (186Re) Obisbemeda for Treatment of Recurrent Glioblastoma Jan 19
Plus Therapeutics Receives Second Letter from Nasdaq Regarding Minimum Bid Price Requirement Nov 29
Plus Therapeutics Provides Updates on ReSPECT™ Clinical Trials Nov 20
High number of new and inexperienced directors Nov 16
Plus Therapeutics to Provide Update on Respect(Tm) Clinical Trials At the 27Th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology Nov 03
Plus Therapeutics, Inc. Announces Selection of Rhenium (186Re) Obisbemeda as International Non-Proprietary Name for 186RNL Oct 27
Plus Therapeutics, Inc. to Report Q3, 2022 Results on Oct 20, 2022 Oct 07
Plus Therapeutics, Inc. Receives Product Development Research Grant by the Cancer Prevention and Research Institute of Texas Sep 23
Plus Therapeutics Presents Positive Phase 1 Data from ReSPECT-GBM Clinical Trial at the European Society for Medical Oncology Congress 2022 Sep 13
Plus Therapeutics, Inc. Announces Summary of FDA Meeting Aug 30
Plus Therapeutics, Inc. (NasdaqCM:PSTV) announces an Equity Buyback for $2 million worth of its shares. Aug 16
Plus Therapeutics, Inc. Presents Positive Data from Ongoing ReSPECT™ Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases Aug 14
Plus Therapeutics, Inc. to Report Q2, 2022 Results on Jul 21, 2022 Jul 14
Plus Therapeutics Completes Enrollment of Cohort 1 Respect-Lm Phase 1/2A Trial Jun 17
Plus Therapeutics Reports Positive Clinical Outcomes from ReSPECT-GBM Trial at the Society of Nuclear Medicine and Molecular Imaging 2022 Annual Meeting Jun 14
Plus Therapeutics Receives Non-Compliance Notice from the Nasdaq Stock Market May 29
High number of new and inexperienced directors Apr 27
Plus Therapeutics, Inc. to Report Q1, 2022 Results on Apr 21, 2022 Apr 15
Plus Therapeutics, Inc., Annual General Meeting, May 16, 2022 Apr 08
Plus Therapeutics, Inc. to Report Q4, 2021 Results on Feb 24, 2022 Feb 19
Plus Successfully Treats First Patient in Latest Dosing Cohort in ReSPECT-GBM Trial Jul 24
Revenue beats expectations Feb 24
Full year 2020 earnings released: US$1.86 loss per share (vs US$2.77 loss in FY 2019) Feb 24
Plus Therapeutics, Inc. Provides Update on Rhenium NanoLiposome (RNL™) Program Feb 23
New 90-day high: €2.96 Feb 16
Plus Therapeutics, Inc. to Report Q4, 2020 Results on Feb 22, 2021 Feb 12
New 90-day high: €2.36 Jan 26
Plus Therapeutics, Inc Enters Master Services Agreement with Piramal Pharma Solutions, Inc Jan 13
Plus Therapeutics, Inc. Completes Sixth Dosing Cohort in ReSPECT™ Glioblastoma Trial Dec 17
New 90-day low: €1.68 Dec 03
Plus Therapeutics Expands ReSPECT™ Clinical Trial to MD Anderson Cancer Center Dec 02
Plus Therapeutics, Inc. Announces Positive Interim Data from ReSPECT™ Phase 1 Clinical Trial in Recurrent Glioblastoma Nov 20
Plus Therapeutics Announces Formation of Scientific Advisory Board Nov 06 Shareholder Returns XMP0 DE Biotechs DE Market 7D 1.4% 6.5% 1.3% 1Y -38.2% -1.9% 9.0%
See full shareholder returns
Return vs Market: XMP0 underperformed the German Market which returned 9% over the past year.
Price Volatility Is XMP0's price volatile compared to industry and market? XMP0 volatility XMP0 Average Weekly Movement 10.1% Biotechs Industry Average Movement 7.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: XMP0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: XMP0's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection.
Show more Plus Therapeutics, Inc. Fundamentals Summary How do Plus Therapeutics's earnings and revenue compare to its market cap? XMP0 fundamental statistics Market cap €6.68m Earnings (TTM ) -€12.58m Revenue (TTM ) €5.59m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) XMP0 income statement (TTM ) Revenue US$5.73m Cost of Revenue US$11.19m Gross Profit -US$5.46m Other Expenses US$7.42m Earnings -US$12.88m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -2.19 Gross Margin -95.42% Net Profit Margin -225.07% Debt/Equity Ratio -63.6%
How did XMP0 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/12 07:31 End of Day Share Price 2025/01/10 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Plus Therapeutics, Inc. is covered by 14 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Edward Woo Ascendiant Capital Markets LLC Andrew D'Silva B. Riley Securities, Inc. John Savin Edison Investment Research
Show 11 more analysts 
